Summary
Mass spectrometry (MS) is a widely applied analytical tool underpinning important commercial sectors like biotechnology, pharmaceutics, and environmental analysis. A significant drawback is that the analysis is destructive, resulting in irretrievable sample loss and making MS nonideal when sample is expensive or scarce. We pioneered a technology capable of reducing the amount of sample consumed during MS by >4000 times compared to the existing state-of-the-art by using picolitre (10^-12 L) droplets. Because these sample volumes are so small, our technology will significantly accelerate otherwise time-consuming preparative chemistry, benefitting end users in the above-mentioned sectors. Anticipated commercial benefits include improved cost-effectiveness and increased productivity gains arising from >99.9% cost savings on samples and substantial cost savings on staff time. The commercial adoption of our technology will lead to new services and increased sales by enabling analysis of samples too scarce for current technologies. The considerable reduction in sample consumption will provide environmental benefits, and the capability to accelerate e.g. the drug discovery process may yield health benefits. Consequently, our picodroplet MS technology has the potential to become the method of choice for a diverse range of MS end users. To achieve these envisioned impacts, we will develop relationships with key industrial stakeholders in the analytical instrumentation sector and, building on our recent patent application, advance our IPR strategy by evaluating market and licensee requirements. We will engage directly with leading MS end users to quantify the benefits of our technology in the important application areas of reaction discovery, biomolecular analysis, and environmental sampling. This PoC will facilitate comprehensive evaluation of our technology’s strengths relative to competitors and maximise its commercial potential.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101188956 |
| Start date: | 01-01-2025 |
| End date: | 30-06-2026 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Mass spectrometry (MS) is a widely applied analytical tool underpinning important commercial sectors like biotechnology, pharmaceutics, and environmental analysis. A significant drawback is that the analysis is destructive, resulting in irretrievable sample loss and making MS nonideal when sample is expensive or scarce. We pioneered a technology capable of reducing the amount of sample consumed during MS by >4000 times compared to the existing state-of-the-art by using picolitre (10^-12 L) droplets. Because these sample volumes are so small, our technology will significantly accelerate otherwise time-consuming preparative chemistry, benefitting end users in the above-mentioned sectors. Anticipated commercial benefits include improved cost-effectiveness and increased productivity gains arising from >99.9% cost savings on samples and substantial cost savings on staff time. The commercial adoption of our technology will lead to new services and increased sales by enabling analysis of samples too scarce for current technologies. The considerable reduction in sample consumption will provide environmental benefits, and the capability to accelerate e.g. the drug discovery process may yield health benefits. Consequently, our picodroplet MS technology has the potential to become the method of choice for a diverse range of MS end users. To achieve these envisioned impacts, we will develop relationships with key industrial stakeholders in the analytical instrumentation sector and, building on our recent patent application, advance our IPR strategy by evaluating market and licensee requirements. We will engage directly with leading MS end users to quantify the benefits of our technology in the important application areas of reaction discovery, biomolecular analysis, and environmental sampling. This PoC will facilitate comprehensive evaluation of our technology’s strengths relative to competitors and maximise its commercial potential.Status
SIGNEDCall topic
ERC-2024-POCUpdate Date
22-11-2024
Images
No images available.
Geographical location(s)
